Crinetics Pharmaceuticals Future Growth
Future criteria checks 2/6
Crinetics Pharmaceuticals is forecast to grow earnings and revenue by 24.7% and 52.2% per annum respectively. EPS is expected to grow by 27.4% per annum. Return on equity is forecast to be -47.5% in 3 years.
Key information
24.7%
Earnings growth rate
27.4%
EPS growth rate
| Biotechs earnings growth | 21.2% |
| Revenue growth rate | 52.2% |
| Future return on equity | -47.5% |
| Analyst coverage | Good |
| Last updated | 27 Mar 2024 |
Recent future growth updates
Recent updates
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
Mar 21Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
Jan 27
Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares
Dec 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 88 | -276 | -252 | -224 | 7 |
| 12/31/2025 | 28 | -272 | -214 | -210 | 11 |
| 12/31/2024 | 1 | -245 | -209 | -223 | 11 |
| 12/31/2023 | 4 | -215 | -171 | -166 | N/A |
| 9/30/2023 | 5 | -199 | -167 | -163 | N/A |
| 6/30/2023 | 5 | -184 | -161 | -160 | N/A |
| 3/31/2023 | 4 | -175 | -144 | -142 | N/A |
| 12/31/2022 | 5 | -164 | -117 | -115 | N/A |
| 9/30/2022 | 5 | -150 | -104 | -103 | N/A |
| 6/30/2022 | 5 | -136 | -91 | -90 | N/A |
| 3/31/2022 | 4 | -119 | -82 | -82 | N/A |
| 12/31/2021 | 1 | -108 | -89 | -89 | N/A |
| 9/30/2021 | N/A | -98 | -82 | -82 | N/A |
| 6/30/2021 | N/A | -89 | -74 | -74 | N/A |
| 3/31/2021 | N/A | -79 | -70 | -70 | N/A |
| 12/31/2020 | 0 | -74 | -62 | -62 | N/A |
| 9/30/2020 | 0 | -67 | -60 | -60 | N/A |
| 6/30/2020 | 1 | -63 | -55 | -55 | N/A |
| 3/31/2020 | 1 | -59 | -52 | -52 | N/A |
| 12/31/2019 | 1 | -50 | -47 | -46 | N/A |
| 9/30/2019 | 2 | -44 | -40 | -39 | N/A |
| 6/30/2019 | 2 | -38 | -32 | -31 | N/A |
| 3/31/2019 | 2 | -31 | -24 | -23 | N/A |
| 12/31/2018 | 2 | -27 | -21 | -19 | N/A |
| 9/30/2018 | 2 | -21 | -17 | -16 | N/A |
| 6/30/2018 | 2 | -16 | -13 | -13 | N/A |
| 3/31/2018 | 2 | -12 | -11 | -11 | N/A |
| 12/31/2017 | 2 | -9 | -10 | -9 | N/A |
| 12/31/2016 | 1 | -6 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Market: CRNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRNX's revenue (52.2% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: CRNX's revenue (52.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRNX is forecast to be unprofitable in 3 years.